Martin & Co. Inc. TN Reduces Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Martin & Co. Inc. TN lessened its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 9.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 93,743 shares of the company’s stock after selling 10,302 shares during the quarter. Martin & Co. Inc. TN’s holdings in Omnicell were worth $4,173,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. boosted its stake in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell in the third quarter valued at $32,721,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after acquiring an additional 243,353 shares in the last quarter. Finally, Pier Capital LLC acquired a new position in Omnicell in the third quarter valued at $5,859,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 1.5 %

Shares of OMCL opened at $39.61 on Monday. The stock has a fifty day moving average of $43.64 and a two-hundred day moving average of $43.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.95 and a current ratio of 1.37. The company has a market capitalization of $1.83 billion, a PE ratio of 146.71, a price-to-earnings-growth ratio of 26.98 and a beta of 0.78. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, analysts forecast that Omnicell, Inc. will post 1.04 EPS for the current year.

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on OMCL shares. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company dropped their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus target price of $52.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.